National HIV CurriculumLogo
Common TitleMK-8591A-052
Official Title A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in Participants With HIV-1 Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)
Phase Phase III
ClinicalTrials.gov NCT05630755
Treatments
Doravirine-Islatravir

Doravirine-Islatravir

Tradename:IdvynsoClass:Single-Tablet Regimens
Funding
IndustryMerck Sharp & Dohme
TagsTwo-drug regimen

Share by e-mail

The Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS) provided financial support for this website. The award provided 100% of total costs and totaled $1,172,990. The contents are those of the author. They may not reflect the policies of HRSA, HHS, or the U.S. Government.

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.